A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

PTCL Clinical Trial

Official title:
A Single-arm, Open, Multicenter, Phase II Study to Investigate the Efficacy and Safety of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

Status Not yet recruiting

Clinical Trial Summary

A single-arm, open, multicenter study to investigate the efficacy and safety of YY-20394, an oral small molecular inhibitor of PI3K-delta, in patients with relapsed or refractory peripheral T/NK cell lymphoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04705090
Study type	Interventional
Source	Shanghai YingLi Pharmaceutical Co. Ltd.
Contact	Hanying Bao, MD,PhD
Phone	86 21-51370693
Email	hybao@yl-pharma.com
Status	Not yet recruiting
Phase	Phase 2
Start date	April 2021
Completion date	June 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03900442` - Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort	Phase 1
Withdrawn	`NCT02757248` - Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL	Phase 1
Not yet recruiting	`NCT05238064` - Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL	Phase 1/Phase 2
Recruiting	`NCT03240211` - Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL	Phase 1
Recruiting	`NCT04747236` - Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL	Phase 2
Completed	`NCT03493451` - Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms	Phase 2
Recruiting	`NCT05967949` - A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.
Recruiting	`NCT03884205` - GDPE/CEOPE Compared With CEOPE for Newly Diagnosed Patients With PTCL